OTONOMY INC (OTIC) Stock Price, Forecast & Analysis
USA - NASDAQ:OTIC - US68906L1052 - Common Stock
OTIC Key Statistics, Chart & Performance
The current stock price of OTIC is 0.077 USD. In the past month the price decreased by -29.87%. In the past year, price decreased by -96.65%.
OTIC Latest News, Press Relases and Analysis
OTIC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.8 | 974.12B | ||
| JNJ | JOHNSON & JOHNSON | 18.95 | 473.62B | ||
| MRK | MERCK & CO. INC. | 10.65 | 234.40B | ||
| PFE | PFIZER INC | 7.86 | 143.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.14 | 95.39B | ||
| ZTS | ZOETIS INC | 19.13 | 53.74B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.89B | ||
| VTRS | VIATRIS INC | 4.62 | 12.56B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.1 | 10.54B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.23 | 7.90B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.96B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.65 | 3.95B |
Related stock screener links
About OTIC
Company Profile
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Company Info
OTONOMY INC
5626 Oberlin Drive, Suite 100
San Diego CALIFORNIA 92121 US
CEO: David A. Weber
Employees: 51
Phone: 18587687823.0
OTONOMY INC / OTIC FAQ
What does OTIC do?
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
What is the stock price of OTONOMY INC today?
The current stock price of OTIC is 0.077 USD. The price decreased by -11.19% in the last trading session.
Does OTIC stock pay dividends?
OTIC does not pay a dividend.
What is the ChartMill rating of OTONOMY INC stock?
OTIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of OTONOMY INC (OTIC) based on its PE ratio?
OTONOMY INC (OTIC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
What is the market capitalization of OTIC stock?
OTONOMY INC (OTIC) has a market capitalization of 4.40M USD. This makes OTIC a Nano Cap stock.
OTIC Technical Analysis
OTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTIC. OTIC has a bad profitability rating. Also its financial health evaluation is rather negative.
OTIC Financial Highlights
Over the last trailing twelve months OTIC reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 4.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |
OTIC Forecast & Estimates
9 analysts have analysed OTIC and the average price target is 9.18 USD. This implies a price increase of 11822.08% is expected in the next year compared to the current price of 0.077.
For the next year, analysts expect an EPS growth of 3.04% and a revenue growth -100% for OTIC